Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/222074
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity |
Autor: | Ramírez-Moya, Julia CSIC ORCID; Baker, Allison R.; Slack, Frank J.; Santisteban, Pilar CSIC ORCID | Fecha de publicación: | 2020 | Editor: | Springer Nature | Citación: | Oncogene 39: 3738–3753 (2020) | Resumen: | Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA. A-to-I editing of RNA is a widespread posttranscriptional process that has recently emerged as an important mechanism in cancer biology. A-to-I editing levels are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent mechanisms governing thyroid cancer progression are unexplored. To address the importance of RNA A-to-I editing in thyroid cancer, we examined the role of ADAR1. Loss-of-function analysis showed that ADAR1 suppression profoundly repressed proliferation, invasion, and migration in thyroid tumor cell models. These observations were validated in an in vivo xenograft model, which showed that ADAR1-silenced cells had a diminished ability to form tumors. RNA editing of miRNAs has the potential to markedly alter target recognition. According to TCGA data, the tumor suppressor miR-200b is overedited in thyroid tumors, and its levels of editing correlate with a worse progression-free survival and disease stage. We confirmed miR-200b overediting in thyroid tumors and we showed that edited miR-200b has weakened activity against its target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggressiveness of ADAR1-silenced cells. We also found that RAS, but not BRAF, modulates ADAR1 levels, an effect mediated predominantly by PI3K and in part by MAPK. Lastly, pharmacological inhibition of ADAR1 activity with the editing inhibitor 8-azaadenosine reduced cancer cell aggressiveness. Overall, our data implicate ADAR1-mediated A-to-I editing as an important pathway in thyroid cancer progression, and highlight RNA editing as a potential therapeutic target in thyroid cancer. | Versión del editor: | https://doi.org/10.1038/s41388-020-1248-x | URI: | http://hdl.handle.net/10261/222074 | DOI: | 10.1038/s41388-020-1248-x | ISSN: | 0950-9232 |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
adaracti.pdf | 1,92 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
34
checked on 13-mar-2024
SCOPUSTM
Citations
53
checked on 20-mar-2024
WEB OF SCIENCETM
Citations
52
checked on 25-feb-2024
Page view(s)
112
checked on 28-mar-2024
Download(s)
123
checked on 28-mar-2024